Becton, Dickinson 2026 Q4 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Q4 revenue was $5.3 billion, up 5.6%, and adjusted EPS was $4.15, up 27.3%; excluding the Alaris prior year comparison, revenue growth was high single digits.
- For fiscal '26, revenue was $19.5 billion, up 3.9%, and adjusted EPS was $12.70, up 6.7%.
- Growth was broad-based, with double-digit growth across advanced patient monitoring, PureWick, advanced tissue regeneration, biologic drug delivery, and Roa Pharmacy Automation.
- Fiscal '26 adjusted gross margin was 55.1% and adjusted operating margin was 25%, down 10 and 20 basis points respectively; tariffs had a 90 basis point impact, mostly offset by BD excellence and favorable mix.
- Full year free cash flow was $2.9 billion, up 42%, and free cash flow conversion increased from approximately 57% to 74%, including separation costs.
- BD returned $3.6 billion to shareholders in fiscal '26, including approximately $2.4 billion in share repurchases and $1.2 billion in dividends, and paid down $2.4 billion in debt.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, press star 0, and a member of our team will be happy to help you. Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star 0, and a member of our team will be happy to help you. Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star 0, and a member of our team will be happy to help you. Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star 0, and a member of our team will be happy to help you. Hello, and welcome to BD's fourth quarter and full year fiscal 2026 earnings call.
At the request of BD, today's call is being recorded and will be available for replay on BD's investor relations website, investors.bd.com, or by phone at 800-677-7085 for domestic calls, and area code +1-402-220-0665 for international calls. For today's call, all parties have been placed in a listen-only mode until the question-and-answer session. I will now turn the call over to Shawn Bevec, Senior Vice President, Investor Relations.
Good morning, and welcome to BD's earnings call. I'm Shawn Bevec, Senior Vice President of Investor Relations. Thank you for joining us. This call is being made available via audio webcast at bd.com. Earlier this morning, BD released its results for the fourth quarter and full year fiscal 2026. The press release and presentation can be accessed on the IR website at investors.bd.com. Leading today's call are Tom Polen, BD's Chairman, Chief Executive Officer, and President, and Vitor Roque, Executive Vice President and Chief Financial Officer. Before we get started, I want to remind you that we will be making forward-looking statements. You can read the disclaimer in our earnings release and the disclosures in our SEC filings on our investor relations website. Unless otherwise specified, all comparisons will be made on a year-on-year basis versus the relevant fiscal period.
Revenue percentage changes are on an FX-neutral basis unless otherwise noted. Also, references to adjusted EPS refer to adjusted diluted EPS. The financials discussed here and included in the earnings release are presented on a continuing operations basis. Prior periods have been recast to reflect the spin-off of our life sciences business in combination with Waters, which is accounted for as discontinued operations. Reconciliations between GAAP and non-GAAP measures are included in the appendices of our earnings release and presentation. With that, I will turn it over to Tom.
Thank you, Shawn, and good morning, everyone. Earlier today, we reported strong Q4 results with revenue of $5.3 billion, up 5.6%, and 27.3% growth in adjusted EPS to $4.15. For the full year, we delivered $19.5 billion in revenue, up 3.9%, and 6.7% growth in adjusted EPS to $12.70. Growth remained broad-based, with momentum across all our businesses. Excluding the Alaris prior year comparison, we delivered high single-digit revenue growth in Q4 and solid mid-single-digit growth for the full year. Growth was led by the key platforms where we've been investing, including Advanced Patient Monitoring, PureWick, advanced tissue regeneration, biologic drug delivery, and Rowa pharmacy automation, all of which delivered double-digit growth with accretive margins in both Q4 and the full year.
Importantly, FY 2026 marks a significant milestone, completing BD's transformation to a more focused medtech company with the separation of our life sciences business. New BD is doing exactly what we designed it to do, demonstrating the growth and earnings potential of our focused portfolio through commercial and innovation momentum across our key growth platforms, delivering strong operational execution, and the expanding impact of BD Excellence. Before we get into more details on the quarter, I want to highlight our recent landmark partnership with the U.S. government, which reflects BD's important role in the U.S. healthcare infrastructure and a shared commitment to expand domestic manufacturing capacity and strengthen access to essential medical technologies. Through this agreement, we committed to invest $19 billion in the U.S. over several years, with $3 billion of the overall investment directed toward manufacturing expansion.
Importantly, this does not represent incremental investment for BD, rather a reprioritization of investments toward the U.S. to support domestic manufacturing and supply chain resiliency. The partnership also provides relief from future tariffs imposed under Section 232 on covered BD products and inputs, subject to the final scope and implementation of any future Section 232 actions and BD's achievement of agreed milestones. We've already mobilized the organization and begun taking action to deliver on these commitments. Turning to our New BD strategy. We're seeing clear progress against our three strategic pillars: compete, innovate, and deliver. Our growing commercial, innovation, and operational capabilities are strengthening the quality of our growth while improving earnings power and cash flow. Starting with compete. We've been raising the bar on commercial execution across BD, investing in every part of the commercial flywheel.
That spans talent, AI sales tools, a disciplined sales process, and new pay-for-performance compensation plans, all powered by BD Excellence and a relentless focus on solving customer challenges with speed and urgency. In Q4, this translated into measurable outcomes across the company. Within Connected Care, commercial execution continued to drive share gains and new adoption across all platforms. In Advanced Patient Monitoring, sales force investments are driving uptake of HemoSphere Alta that contributed to strong capital growth in Q4. APM continues to perform well ahead of the deal model, generating one of its highest annual growth rates in the last 20 years, while significantly expanding margins under BD's ownership by applying BD Excellence in APM manufacturing. Alaris finished the year with strong competitive momentum, gaining additional share in Q4 and more than 250 basis points for the full year.
Dispensing also continued to gain share, with strong Pyxis Pro order momentum and a 95% attachment rate of our new Incada AI platform. This strong early adoption reflects high customer interest in our new BD AI platform and supports our strategy to build recurring software, analytics, and AI revenue. In Pharmacy Automation, incremental investments we made coming into the year are delivering results. We are seeing increased central fill win rates and an improving growth outlook, aided by the recent U.S. launch of BD Vmax. We exited the year with strong commercial momentum, winning all six central fill opportunities we competed for in Q4, with Vmax attached to every sale, reinforcing the strength of our portfolio in the growing U.S. healthcare system central fill market. In BioPharma Systems, we expanded our position in next-generation biologic drug delivery, including continued momentum in delivering GLP-1 therapies.
In Interventional, incremental commercial investments are translating to stronger growth, with PI accelerating each quarter throughout the year. In UCC, PureWick delivered another quarter of double-digit growth, driven by continued adoption, competitive wins, and momentum in the VA channel. Across the portfolio, we are seeing our commercial investments translate into stronger growth and competitive performance. We have added resources in priority areas, introduced new tools, applied BD Excellence to commercial execution, and better aligned incentives with our growth priorities. These actions are raising execution across New BD. Our second priority is innovate. We are concentrating investments in attractive markets where healthcare needs BD most and where we believe BD can create sustainable competitive advantage. This is in Connected Care, enabling the shift to newer low-cost settings and advancing the treatment of chronic disease. Earlier this year, we moved more R&D resources and decision-making closer to the businesses.
We increased investments behind our six key growth platforms, and our pipeline is expanding. We also deployed BD Excellence into R&D this year and are introducing new products faster, having compressed launch times by an average of 10 months. In Q4, we received FDA approval for Liverty TIPS Stent Graft, and we are seeing strong customer interest. In a market that has seen limited innovation for many years, Liverty brings enhanced ease of use, the broadest range of lengths, and compelling clinical data, broadening BD's presence in the approximately $2 billion global venous market, which is growing high single digits. We recently received 510(k) clearance for Phasix ST Parastomal, a first-of-its-kind resorbable mesh designed specifically for parastomal hernia repairs. It is an underserved market with significant unmet clinical needs.
With the launch expected in the first half of fiscal 2027, this innovation further expands our advanced tissue regeneration portfolio and strengthens our position in the $1.8 billion served market. We are increasingly seeing the benefits of the strategic choices and investments we have made over the last several years. Combined with our strength in innovation capabilities and execution, we are building a robust pipeline and look forward to sharing more at our upcoming investor day next month. Our third priority, deliver, is about operational excellence at scale. It is about improving quality, service, productivity, margin, and cash flow. Through BD Excellence, we have built one of the most resilient supply chains in our industry, which combined with our scale, has become a meaningful competitive advantage. In fiscal 2026, we delivered approximately 8% gross productivity in our plants, with customer service levels above 90%.
This was driven by more than 2,000 Kaizen events, resulting in higher manufacturing efficiencies and raw material savings, as well as ongoing network optimization. We are also generating value from the $200 million cost-out program launched at the beginning of fiscal 2026, with 100% of the savings now identified. Turning to capital allocation, our disciplined framework remains unchanged. Importantly, we are seeing our operational progress translate into stronger cash generation. As free cash flow improves, so does our capacity to invest organically, return capital to shareholders, and pursue focused tuck-in M&A. This will continue to increase as we drive towards our 90% free cash flow conversion target over time. In summary, fiscal 2026 was an important year for BD. We completed our portfolio transformation to a pure-play medtech company.
We strengthened execution and increasingly saw the benefits of the strategic choices and investments we have made over the last several years. Our differentiated growth platforms are strengthening our portfolio and expanding our opportunities for growth. We enter fiscal 2027 with a more focused portfolio, and we have confidence in the underlying trajectory of New BD and our path towards sustainable mid-single-digit growth. Looking ahead, we see a compelling opportunity to combine that growth with continued earnings expansion and a step change in cash flow generation to drive long-term value creation. We are still early in realizing the full potential of New BD, and we look forward to laying out that opportunity in greater detail at our investor day on December 10th. With that, I will turn it over to Vitor to provide more detail on our financial performance and guidance.
Thanks, Tom, and good morning, everyone. We delivered a strong quarter with $5.3 billion in revenue, up 5.6%. Excluding the Alaris prior year comparison, revenue growth was high single digits. As Tom highlighted, performance was broad-based, driven by continued double-digit growth across multiple key platforms and strong U.S. performance. Medical Essentials grew 5.9%. In MDS, solid mid-single-digit growth was driven by share gains and healthy utilization across the vascular access management portfolio. In Specimen Management, high single-digit growth was driven by share gains across the BD Vacutainer portfolio, new supply capacity, and incremental demand as customers continue to work through competitor disruptions. Connected Care grew 2.1%, led by double-digit growth in Advanced Patient Monitoring, with strength in both capital and consumables. MMS declined low single digits due to difficult prior year comparison in Alaris Capital.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
